Voyager Therapeutics

Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics was launched in 2014 with funding from leading life sciences investor Third Rock Ventures and is headquartered in Cambridge, Mass.
Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2014
Size (employees)
52 (est)
Voyager Therapeutics was founded in 2014 and is headquartered in Cambridge, US

Key People/Management at Voyager Therapeutics

Mark Kay

Mark Kay

Founder
Phillip D. Zamore

Phillip D. Zamore

Founder
Guangping Gao

Guangping Gao

Founder
Krystof Bankiewicz

Krystof Bankiewicz

Founder
Jeff Goater

Jeff Goater

Vice President of Business Development
James Geraghty

James Geraghty

Interim Chief Business Officer

Voyager Therapeutics Office Locations

Voyager Therapeutics has an office in Cambridge
Cambridge, US (HQ)
75 Sidney St

Voyager Therapeutics Financials and Metrics

Voyager Therapeutics Financials

Voyager Therapeutics's revenue was reported to be $14.2 m in FY, 2016
USD

Net income (Q1, 2017)

(16.6 m)

Market capitalization (13-Nov-2017)

320.8 m
Voyager Therapeutics's current market capitalization is $320.8 m.
USDFY, 2015FY, 2016

Revenue

17.3 m14.2 m

Revenue growth, %

(18%)

EBITDA

(20.5 m)(41.3 m)

EBITDA margin, %

(118%)(290%)
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(22.4 m)(7.2 m)(16.5 m)(25.5 m)(16.6 m)
USDFY, 2015FY, 2016

Accounts Receivable

826 m

Current Assets

195.9 m178.8 m

PP&E

3.2 m7.9 m

Total Assets

229.5 m189.6 m
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

66.5 m33.9 m67 m

Current Assets

108.6 m205.7 m205.5 m193 m161.1 m144.7 m

PP&E

3.3 m3.6 m3.6 m4.3 m10.1 m10.7 m

Total Assets

166.4 m220 m209.8 m202 m175.1 m158.4 m
USDFY, 2015FY, 2016

Net Income

(3.8 m)(40.2 m)

Depreciation and Amortization

600 k612 k

Inventories

(234 k)(847 k)

Accounts Payable

950 k(62 k)
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(22.4 m)(7.2 m)(16.5 m)(25.5 m)(16.6 m)(35.5 m)

Depreciation and Amortization

436 k136 k288 k448 k317 k726 k

Accounts Payable

(1 m)1.1 m(158 k)175 k280 k(243 k)

Cash From Operating Activities

50.9 m(9.5 m)(19.2 m)(29.4 m)(14.3 m)(30.6 m)
Show all financial metrics

Voyager Therapeutics Operating Metrics

Voyager Therapeutics's Patent Applications was reported to be 28 in FY, 2016
FY, 2016

Patent Applications

28

Patents Issued

157
Show all operating metrics

Voyager Therapeutics Market Value History

Voyager Therapeutics's Web-traffic and Trends

Voyager Therapeutics Company Life and Culture

You may also be interested in